Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243


Attention-Deficit/Hyperactivity Disorder: A Historical Neuropsychological Perspective.

Mahone EM, Denckla MB.

J Int Neuropsychol Soc. 2017 Oct;23(9-10):916-929. doi: 10.1017/S1355617717000807.


Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.

J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.


Cognitive-Behavioral Therapy for a 9-Year-Old Girl With Disruptive Mood Dysregulation Disorder.

Tudor ME, Ibrahim K, Bertschinger E, Piasecka J, Sukhodolsky DG.

Clin Case Stud. 2016 Dec;15(6):459-475. doi: 10.1177/1534650116669431. Epub 2016 Sep 22.


Relationship between subtypes and symptoms of ADHD, insomnia, and nightmares in connection with quality of life in children.

Grünwald J, Schlarb AA.

Neuropsychiatr Dis Treat. 2017 Sep 5;13:2341-2350. doi: 10.2147/NDT.S118076. eCollection 2017.


Association of Risk of Suicide Attempts With Methylphenidate Treatment.

Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK.

JAMA Psychiatry. 2017 Oct 1;74(10):1048-1055. doi: 10.1001/jamapsychiatry.2017.2183.


A Pharmacologic Algorithm for Youth Who Are at High Risk for Bipolar Disorder.

Schneck CD, Chang KD, Singh MK, DelBello MP, Miklowitz DJ.

J Child Adolesc Psychopharmacol. 2017 Nov;27(9):796-805. doi: 10.1089/cap.2017.0035. Epub 2017 Jul 21.


A National Profile of Attention-Deficit Hyperactivity Disorder Diagnosis and Treatment Among US Children Aged 2 to 5 Years.

Danielson ML, Visser SN, Gleason MM, Peacock G, Claussen AH, Blumberg SJ.

J Dev Behav Pediatr. 2017 Sep;38(7):455-464. doi: 10.1097/DBP.0000000000000477.


The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.

Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, Catalá MA, Tabarés-Seisdedos R, Moher D.

PLoS One. 2017 Jul 12;12(7):e0180355. doi: 10.1371/journal.pone.0180355. eCollection 2017.


ADHD Medication and Substance-Related Problems.

Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, Sjölander A, Lichtenstein P, Larsson H, D'Onofrio BM.

Am J Psychiatry. 2017 Sep 1;174(9):877-885. doi: 10.1176/appi.ajp.2017.16060686. Epub 2017 Jun 29.


Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.

Holmskov M, Storebø OJ, Moreira-Maia CR, Ramstad E, Magnusson FL, Krogh HB, Groth C, Gillies D, Zwi M, Skoog M, Gluud C, Simonsen E.

PLoS One. 2017 Jun 15;12(6):e0178187. doi: 10.1371/journal.pone.0178187. eCollection 2017. Review.


Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699. doi: 10.1089/cap.2016.0177. Epub 2017 May 30.


Executive function in childhood obesity: Promising intervention strategies to optimize treatment outcomes.

Hayes JF, Eichen DM, Barch DM, Wilfley DE.

Appetite. 2017 May 26. pii: S0195-6663(17)30154-X. doi: 10.1016/j.appet.2017.05.040. [Epub ahead of print] Review.


Specific Components of Pediatricians' Medication-Related Care Predict Attention-Deficit/Hyperactivity Disorder Symptom Improvement.

Epstein JN, Kelleher KJ, Baum R, Brinkman WB, Peugh J, Gardner W, Lichtenstein P, Langberg JM.

J Am Acad Child Adolesc Psychiatry. 2017 Jun;56(6):483-490.e1. doi: 10.1016/j.jaac.2017.03.014. Epub 2017 Apr 5.


Italian regional health service costs for diagnosis and 1-year treatment of ADHD in children and adolescents.

Casadei G, Cartabia M, Reale L, Costantino MA, Bonati M; Lombardy ADHD Group.

Int J Ment Health Syst. 2017 Apr 28;11:33. doi: 10.1186/s13033-017-0140-8. eCollection 2017.


Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial.

Tamm L, Denton CA, Epstein JN, Schatschneider C, Taylor H, Arnold LE, Bukstein O, Anixt J, Koshy A, Newman NC, Maltinsky J, Brinson P, Loren REA, Prasad MR, Ewing-Cobbs L, Vaughn A.

J Consult Clin Psychol. 2017 May;85(5):434-446. doi: 10.1037/ccp0000170. Epub 2017 Mar 23.


Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States.

Nyarko KA, Grosse SD, Danielson ML, Holbrook JR, Visser SN, Shapira SK.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):731-734. doi: 10.1089/cap.2016.0196. Epub 2017 Mar 22.


Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK; ADDUCE consortium.

CNS Drugs. 2017 Mar;31(3):199-215. doi: 10.1007/s40263-017-0410-7. Review.


A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.

Clemow DB, Bushe C, Mancini M, Ossipov MH, Upadhyaya H.

Neuropsychiatr Dis Treat. 2017 Feb 3;13:357-371. doi: 10.2147/NDT.S115707. eCollection 2017. Review.


Supplemental Content

Support Center